Variation of liver SUV on 18FDG-PET/CT studies in women with breast cancer

Clinical Nuclear Medicine

Volumn 38, Issue 6, 2013, Pages 422-425

  Groheux, David ^a,b   Delord, Marc ^b   Rubello, Domenico ^c   Colletti, Patrick M ^d   Nguyen, Minh Loan ^a   Hindié, Elif ^e  

^a Saint Louis Hospital   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c Rovigo Hospital   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

18FDG PET CT; Chemotherapy evaluation; Liver; SUV; Therapy response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INDEPENDENT VARIABLE; LIVER; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AGE FACTORS; AGED; BLOOD GLUCOSE; BODY WEIGHT; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS;

EID: 84877616974     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182872f0e     Document Type: Article

References (17)

1. Groheux D, Giacchetti S, Espié M, et al. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2011;38:419-425.
2. Groheux D, Hindié E, Giacchetti S, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53:249-254.
3. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(suppl 1):122SY150S.
4. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857-1862.
5. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
6. Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53: 1876-1881.
7. Groheux D, Moretti JL, Berenger N, et al. Assessment of response after two cycles of neoadjuvant chemotherapy in locally advanced breast cancer using FDG PET/CT. Eur J Nucl Med Mol Imaging. 2010;37(suppl 2):S236.
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
9. Chin BB, Green ED, Turkington TG, et al. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2009;11:118-122.
10. Beaulieu S, Kinahan P, Tseng J, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J NuclMed. 2003;44:1044-1050.
11. Stahl AR, Heusner TA, Hartung V, et al. Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs. J Nucl Med. 2011;52:18-23.
12. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311-317.
13. Kubota K, Watanabe H, Murata Y, et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nucl Med Biol. 2011;38:347-351.
14. Kamimura K, Nagamachi S, Wakamatsu H, et al. Associations between liver (18)F fluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med. 2010;24:157-161.
15. Berriolo-Riedinger A, Touzery C, Riedinger J-M, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915-1924.
16. Lin CY, Ding HJ, Lin CC, et al. Impact of age on FDG uptake in the liver on PET scan. Clin Imaging. 2010;34:348-350.
17. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.